P855: Variable importance analysis based on gut microbiota and dietary factors between IBD patients and healthy controls in China
ECCO '19 Copenhagen
2019
P856: Compositional changes in the gut microbiota of Korean inflammatory bowel disease patients are linked to clinical phenotypes
ECCO '19 Copenhagen
2019
P857: The microbiota profile reflects disease severity in paediatric onset IBD
ECCO '19 Copenhagen
2019
P858: Impact of ileocaecal resection on gut microbiota in ileal Crohn’s disease patients
ECCO '19 Copenhagen
2019
P859: Hepatitis E seroprevalence in Portuguese inflammatory bowel disease patients under immunosuppression is higher than expected
ECCO '19 Copenhagen
2019
P860: Evaluation of the probiotic features of two different multi-strain probiotic preparations from two different manufacturers
ECCO '19 Copenhagen
2019
P861: Differences in bacteroidal genotypes between newly diagnosed ulcerative colitis patients and healthy controls
ECCO '19 Copenhagen
2019
DOP002: Vedolizumab treatment persistence up to 3 years: post hoc analysis in vedolizumab-naïve patients from the GEMINI LTS studyECCO '18 Vienna
2018
DOP003: Ustekinumab induces clinical and biological remission in biologic refractory Crohn’s disease patients: A real-world belgian cohort studyECCO '18 Vienna
2018
DOP004: Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACYECCO '18 Vienna
2018
DOP005: Safety of vedolizumab in patients naïve to treatment with TNF antagonists compared with patients with prior use of TNF antagonistsECCO '18 Vienna
2018
DOP006: A multicentre cohort study to assess the safety of vedolizumab for inflammatory bowel diseaseECCO '18 Vienna
2018
DOP007: Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha-resistant inflammatory bowel diseaseECCO '18 Vienna
2018
DOP008: Safety of adalimumab in children and adolescents with moderate-to-severe Crohn’s disease: interim results of the CAPE registryECCO '18 Vienna
2018
DOP010: Activating PIK3CD mutations cause severe intestinal lymphonodular hyperplasia and an IBD-like phenotypeECCO '18 Vienna
2018
DOP011: Genotype–phenotype association analysis of inflammatory bowel disease in 6395 East Asian subjects: results from the international IBD Genetics ConsortiumECCO '18 Vienna
2018